Peginterferon alfacon-2 (Beijing Kawin Technology)

培集成干扰素α-2（北京凯因科技）

Report date: 2026/01/22 17:13:21

Base Information

Drug NamePeginterferon alfacon-2 (Beijing Kawin Technology)
Drug Alias Name聚乙二醇化重组集成干扰素变异体注射液Pegylated interferon variant SA (Beijing Kawin Technology)Pegylated Recombinant Consensus Interferon Variant Solution (Beijing Kawin Technology)Peginterferon alfacon-2派益生 +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMyeloproliferative DisordersHemangioendothelioma, EpithelioidHepatitis C, Chronic +[8] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryMainland China
Original Approved Date2018/06/28
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Kawin Technology Share-Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kawin Technology Share-Holding Co Ltd
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsMyeloproliferative DisordersHemangioendothelioma, EpithelioidHepatitis C +[6] 
Inactive IndicationsHepatitis C, ChronicHIV Infections

Other Information

ATC CodeL03AB
Related LinksN/A